Concord Medical Services Holdings Limited (CCM)
NYSE: CCM · Real-Time Price · USD
4.415
+0.035 (0.80%)
Dec 20, 2024, 3:59 PM EST - Market closed
CCM Revenue
Concord Medical Services Holdings had revenue of 218.81M CNY in the half year ending June 30, 2024, with 51.68% growth. This brings the company's revenue in the last twelve months to 471.70M, down -22.97% year-over-year. In the year 2023, Concord Medical Services Holdings had annual revenue of 537.40M with 13.84% growth.
Revenue (ttm)
471.70M CNY
Revenue Growth
-22.97%
P/S Ratio
0.30
Revenue / Employee
648,829 CNY
Employees
727
Market Cap
19.17M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 537.40M | 65.32M | 13.84% |
Dec 31, 2022 | 472.09M | -13.55M | -2.79% |
Dec 31, 2021 | 485.63M | 262.62M | 117.76% |
Dec 31, 2020 | 223.01M | 24.65M | 12.43% |
Dec 31, 2019 | 198.36M | 7.47M | 3.91% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Retractable Technologies | 38.27M |
Bionano Genomics | 33.33M |
BioLineRx | 21.99M |
Bolt Biotherapeutics | 9.78M |
Affimed | 6.29M |
HCW Biologics | 3.50M |
Palatin Technologies | 2.38M |
CCM News
- 12 days ago - Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate - PRNewsWire
- 5 weeks ago - Concord Medical Schedules 2024 Annual Meeting of Shareholders - PRNewsWire
- 3 months ago - Concord Medical Reports Financial Results for the First Half of 2024 - PRNewsWire
- 3 months ago - Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts - Business Wire
- 3 months ago - Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment - PRNewsWire
- 4 months ago - Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris - Business Wire
- 4 months ago - Concord Medical Regains Compliance with NYSE Minimum Price Requirement - PRNewsWire
- 5 months ago - Canagold Intercepts Strong Mineralization in First Five Resource Expansion Drill Holes at New Polaris - Business Wire